Thank you, Dr. de Fronzo!
Keywords:
De Fronzo, diabetes complications, insulin in type 2 diabetes, glycaemia controlAbstract
The authors review the relationship between glycaemia control
and diabetes complications, that is well established and evidence-based concerning microangiopathic complications but rather
controversial in the matter of macroangiopathy. They question
the aims of glucose “blind” control regardless of the actual and individual patient.
The authors recall the De Fronzo´s “octet” concept proposing as
priority the use of insulin sensitivity increasing and beta cell function preserving drugs and calls into question the indiscriminate use of several glycaemia lowering agents (insulin included) because of
their potentially atherogenic role. Insulin could even be considered
the “wrong drug” in preventing cardiovascular diseases.
Downloads
References
De Fronzo, R A – From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 Diabetes Mellitus – Diabetes (2009) 58: 773-795.
G. Sherntharner A.H. Barnrnett et al. -- Is the ADA/EASD Algorithm for the treatment of type 2 diabetes based on evidence or opinion? – Diabetologia (2010) – For Debate-53: 1258-1269, 73-75.
Diabetes Control and Complications Trial Research Group (1993). The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329: 977-986.
Stratton L M. Addler A J et al. (2000) Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. B M J 321: 405-412.
Morrich N J, Wang SL et al. (2001). Mortality and causes of death in the WHO multinational study of vascular diseases in diabetes. Diabetologia 44 (Suppl 2): S14: S21.
Holman RR, Paul SK et al. 10 years follow-up of intensive glucose con control in type 2 diabetes. N Engl J Med (2008). 359:1577-1599.
Currie CJ, Peters JR et al. – Survival as a function of Hb A1c in people with type 2 diabetes: a retrospective cohort study. Lancet (2010) 375: 481-489.
Duchtworth et al. VADT investigators. Glucose control and vascular complications in veterans with type2 diabetes. N Engl J Med (2009) 360: 129-139.
De Fronzo. Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis, the missing links. The Claude Bernard Lecture 2009. Diabetologia (2010); 53: 1270-1287.
Stefano Del Prato, Giuseppe Pens et al. Changing the treatment paradigm for type 2 Diabetes. Diabetes Care (2009) 32: S217:S222.
ADVANCE Collaboration Group. Intensive blood glucose control and vascular outcomes in diabetes type 2 patients. N Engl J Med (2008) 358: 2560-2572.
Intensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials: A position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Diabetes Care January 2009 32:187-192.
The Action to Control Cardiovascular Risk in Diabetes Study Group (2008). Effects of intensive glucose lowering in type 2 diabetes. N Engl
J Med 358: 2545-2559.
Gernstein HC, Miller ME et al. Effects of intensive glucose lowering in type 2 Diabetes. N Engl J Med (2008).358: 2345-2359.
Victor M.Monfort et al. Glycemic control in type 2 D.M. Time for an Evidence-Based About-Face? Annals of Internal Medicine 2009; 150: 803-808.
Eurich D.T, MacAllister et al. Bennefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review. BMJ (2007)-335-497.
Del Prato S, Leonetti F, Simonson DC et al (1994). Effect of sustained physiologic hyperinsulinemia and hyperglycaemia on insulin secretion and insulin sensitivity in man. Diabetologia 37:1025–1035.
Kashyap SR, DeFronzo RA (2007) The insulin resistance syndrome: physiologic considerations. Diab. Vasc Dis. Res 4:13–19.
Tobey TA, Greenfield M et al. Relationship between insulin resistance, insulin secretion, very low density lipoprotein kinetics and plasma triglyceride levels in normotriglyceridemic man. Metabolism (1981) 30:165–171.
Wajchenberg BL. Beta cell failure in diabetes and preservation by clinical treatment Endocr Rev (2007) 28: 187:218.
Chunli Yu, Yan Chen. Mechanism by wich fatty acids inhibit activation of IRS-1 associated PI-3 kinase activity in muscle. The Journal of Biological Chemistry – 2002; De.27.
Hakan Alkhateeb et al. Two phases of palmitate-induced insulin resistance in skeletal muscle – impaired glucose GLUT-4 translocation is followed by reduced GLUT4 intrinsic activity. Am J Phisiol Endocrinol Metab (2007. 2-3; E783-3.
Kashiap S, Belfort R et al. A sustained increase in plasma free fat acid impairs insulin secretion in non-diabetic subjects genetically predisposed to develop type 2 diabetes. Diabetes (2003) 52: 2461-2474.
Kahn SE, HffnerDM et al. Glicemic durability of rosiglitazone, metformin or glyburide monotherapy. N Engl J Med (2006) 355: 2427-2443.
Johnson JA, Majundar SR et. al. Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes. Diabetes Care (2002) 25: 2244-2248.
Hanefeld M et al. Glicemia control and treatement failure with pioglitazone versus glibenclamide in type2 diabetes – a 42 month, open-label observational primary care study. Cur Med Res Opinion (2006) 22:1211-1215.
Tan MH et al. Comparision of pioglitazone and gliclazide in sustaining glycemic control over two years in patients with type 2 diabetes. Diabetes Care (2005) 28: 544-550.
Bajaz et al. Effects of Pioglitazone on intramyocelular fat metabolism in patients type2 Diabetes. J Clin Endocrinol Metabol (2010); 95:1916.
Hausenloy DJ, Yellon. DM GLP-1 therapy: beyond glucose control. Cic. Heart Failure (2008) 1: 147-149.
Madsbad S. Exanatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin Mimetics) – preclinical and clinical results. Best Pract Res Clin Endocrinol Metab (2009) 23: 463-477.
Engel–Nietz NM, Martin S et al. Cardiovascular events and insulin therapy: a retrospective cohort analysis. Diabetes Res Clinic Pract (2008); 81:97:104.
Muis MJ, Bots ML et al. Insulin treatment and cardiovascular disease: friend or foe? A point of view. Diabetes Med. (2005)22:118-126.
De Fronzo RA. Is insulin resistance atherogenic? Possible mechanisms. Atherosclerosis (2006). 7:11-15.
Cruz AB, Amatuzio DS et al. Effect of intra arterial insulin on tissue cholesterol and fatty acids in alloxan diabetic dogs. Circ. Ris. (1961) 9:39-43.
Henry RR, Gumbiner B et al. Intensive conventional insulin therapy for type 2 diabetes. Metabolic effects during 6-month outpatient trial. Diabetes Care (1993); 16:21-31.
Holman RR, Thomo KI et al. Addition of biphasic, prandeal or basal insulin to oral therapy in type 2 diabetes. N Engl J Med (2007) 357:1716:1730.
Giorda CB, Avogaro A et al. Reccurrence of cardiovascular events in patients with type 2 diabetes; Diabetes Care 31; 2154-2159. 35.
JJ Nolan. Consensus guidelines, algorithms and care of the individual patient with type 2 diabetes. Diabetologia. Commentary (2010) 53:1247-1249
Additional Files
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2023 Medicina Interna
Open Access
